Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Coursera Inc (COUR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Coursera Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.85 (market cap $4.49B), while Coursera Inc trades at $5.87 (market cap $1.66B). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 2.7× Coursera Inc's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Coursera Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | COUR | |
|---|---|---|
Market Cap | $4.49B | $1.66B |
Sector | Health | Consumer Staples |
52-Week High | $28.06 | $12.70 |
52-Week Low | $20.06 | $5.09 |
Enterprise Value | $3.69B | $915.98M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Coursera (COUR) trades at $5.80, down 1.69% today, with a bullish technical signal from moving averages. Revenue grew to $757.5M in 2025, though net income remains negative at -$51M. The company completed its merger with Udemy in May 2026, aiming for synergies, and announced a $500M share repurchase program. Positive cash flow from operations of $108.7M supports financial stability.
The outlook is mixed: analyst consensus targets $8.00 (37.9% upside), with 53% buy ratings, but persistent losses and competitive pressures pose risks. Earnings misses in recent quarters highlight execution challenges. The stock offers growth potential via market expansion and merger benefits, yet profitability concerns and market volatility require cautious evaluation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →
